Nov 13, 2018 7:00am EST Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer
Oct 12, 2018 7:00am EDT Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma
Sep 12, 2018 8:00am EDT Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
Aug 13, 2018 8:00am EDT Sutro and The Leukemia & Lymphoma Society Partner on Lymphoma and Multiple Myeloma Treatment
Jul 24, 2018 8:00am EDT Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
Apr 26, 2018 8:00am EDT Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs
Apr 16, 2018 6:30am EDT Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research
